The burgeoning landscape of emerging treatments for body management has seen the rise of both retatrutide and tirzepatide, both dual mechanism agonists targeting the GLP-1 and GIP receptors. While sharing a comparable https://barbaragfov829159.wikitelevisions.com/8711843/retatrutide_vs_tirzepatide_a_comparative_analysis